EXPRESSMOM2 in Pregnant Women at High Risk of Preterm Birth. Aspects of Antenatal Breastmilk Expression and Safety From Gestational Week 28-34 and Potential Nutritional Benefits for the Newborn Infant.

In this randomized controlled study, the investigators aim to examine if antenatal breastmilk expression (aBME) from week 28 in high-risk pregnancies is a safe and effective method to ensure early access to mother's own milk.
In addition, this study will analyze and compare colostrum from pregnancy with colostrum after birth, investigates women's confidence in breastfeeding and breastfeeding establishment as well as measures oxytocin levels during aBME and active labour with no aBME.

开始日期2026-09-01

申办/合作机构

Odense University Hospital

[+1]

NCT07432802

/ Not yet recruitingN/AIIT

Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer - a Randomized, Controlled Trial The STRADOS Trial

In low-risk patients with stage I non-small cell lung cancer (NSCLC) surgical treatment with an anatomical resection is currently the standard of care.
For medically inoperable patients with stage I NSCLC, radiation therapy is currently the standard treatment. The latest generation of radiation therapy modalities is Stereotactic Body Radiation Therapy (SBRT).
In high-risk patients, minimal invasive surgery in terms of sublobar resection (wedge resection) with lymph node sampling is currently the recommended treatment approach for these patients, even though the evidence is limited. Additionally, SBRT is an alternative treatment option but the use in these patients is also based on weak evidence. So, it is highly warranted to compare these two treatment options in this group of patients in a randomized, controlled trial where selection bias can be eliminated. It is the specific aim of this study to provide such a trial allowing an evidence-based approach when deciding between surgery and SBRT as treatment for NSCLC in high-risk patients.
The STRADOS study (STereotactic RADiotherapy Or Surgery) is an open randomized, controlled national multicenter study in which high-risk patients with stage I non-small-cell lung cancer (NSCLC) are randomized to receive either surgical treatment with minimal invasive wedge resection with lymph node sampling, or SBRT.
The overall purpose of the study is to investigate the disease-free survival (DFS) after surgical treatment when compared to SBRT. The primary endpoint is DFS after 3 years. Secondary endpoint is quality of life after 1, 3, 6, 12 and 36 months. Tertiary endpoints are overall survival (OS) after 3 and 5 years; DFS after 5 years; re-admission adverse events and complications after 1, 3, 6, 12 and 36 months; health-care related costs within 12 and 36 months; PRO data - other than quality of life (QoL) (health condition, symptoms and functional level) after 1, 3, 6, 12 and 36 months and lung function test after 12 month.

开始日期2026-09-01

申办/合作机构

Århus Universitetshospital

[+9]

NCT06903728

/ Not yet recruitingN/AIIT

National forsøgsordning Med Glukosesensorer Til Type 2-diabetes: Glukosesensorer Til Gravide Med Type 2-diabetes

The goal of this clinical trial is to evaluate the use of glucose sensors in pregnant women with type 2 diabetes to improve insulin regulation, pregnancy and birth outcomes, and enhance quality of life and satisfaction with treatment.
The main questions it aims to answer are:
* Does the use of glucose sensors during pregnancy lead to a clinically significant reduction in HbA1c by 0.3% at 36 weeks gestation compared to the control group?
* Does the use of glucose sensors during pregnancy result in a clinically significant reduction in mean SD-score for birth weight deviation in newborns compared to the control group?
Researchers will compare the group of women using glucose sensors during pregnancy to a historical control group receiving routine care to see if the sensor improves pregnancy outcomes, glucose control, and birth weights.
Participants will:
* Use a glucose sensor from before 14 weeks of pregnancy until 4-6 weeks postpartum.
* Receive training on how to use the sensor and access ongoing support as needed.
* Have a follow-up appointment 4-6 weeks postpartum, including a consultation for advice on medical treatment and further management of diabetes after birth.

开始日期2026-03-01

申办/合作机构

Odense University Hospital

[+1]

100 项与 Odense University Hospital 相关的临床结果

登录后查看更多信息

0 项与 Odense University Hospital 相关的专利（医药）

登录后查看更多信息

10,729

项与 Odense University Hospital 相关的文献（医药）

2026-12-31·European Clinical Respiratory Journal

Treatment management of patients with lung abscess: a retrospective cohort study

Article

作者: Noerregaard Gissel, Tina ; Sperling, Søren ; Naestholt Dahl, Victor ; Gjoerup, Pia Holland ; Kirkegaard Vaarst, Jakob ; Laursen, Christian Borbjerg ; Bendstrup, Elisabeth ; Fløe, Andreas

Background:

Lung abscesses (LAs) are severe respiratory infections characterised by necrosis of pulmonary tissue. Despite the need for long-term antibiotic treatment, evidence on optimal treatment is limited, and no international guidelines exist. We aimed to evaluate different treatment strategies for treating LAs.

Methods:

Patients hospitalised from 2016 to 2021 with LA were included in a retrospective multicentre cohort study. Descriptive statistics were presented for the current treatment strategies of LA regarding the choice and duration of antibiotic treatment, as well as the use of interventional treatments and associated treatment outcomes.

Results:

In 222 patients diagnosed with LA, 89.2% were treated with intravenous antibiotics for a median duration of 14 days, followed by oral antibiotics for a median of 26 days; 10.8% received oral antibiotics as first-line therapy. Duration of intravenous treatment, total length of antibiotic treatment, and occurrence of treatment failure did not differ across the four most used antibiotic regimens: Benzylpenicillin and metronidazole, piperacillin/tazobactam with or without metronidazole, cefuroxime and metronidazole, or clindamycin monotherapy. Duration of hospitalisation varied slightly between treatment groups, with a trend of the shortest length of stay for patients treated with clindamycin. Fifteen patients underwent interventional treatment. These patients were characterised by larger abscesses, longer duration of antibiotic treatment, and higher mortality.

Conclusions:

Within the limitations of a descriptive design, no significant differences in clinical outcomes of LA were observed across the four most common antibiotic regimens. The selection of regimens varied considerably between the four study sites. Randomised studies are urgently needed to guide the best treatment choice.

2026-12-31·European Clinical Respiratory Journal

Mapping heterogeneity in the management of malignant pleural effusions with indwelling pleural catheters in Denmark - a national survey

Article

作者: Fjaellegaard, Katrine ; Ali, Aras K M ; Laursen, Christian B ; Bødtger, Uffe ; Skaarup, Søren Helbo ; Armbruster, Karin

Background:

Malignant pleural effusion (MPE) affects up to 20% of cancer patients, causing dyspnea and frequent hospitalizations. Treatment includes thoracentesis, pleurodesis, and indwelling pleural catheters (IPC). While UK pleural clinics enhance outpatient care, Denmark lacks a national strategy. This study aims to map the use of IPCs in a Nordic country, focusing on referral, placement, follow-up, and reimbursement of expenses to drainage supplies.

Methods:

A national questionnaire survey was conducted from January to July 2022. The questionnaire, developed by the Danish Respiratory Society's pleural diseases group, covered IPC placement, management, follow-up, and financial aspects. It was distributed to all departments placing IPCs, identified via suppliers and expert input. Data on the number of IPCs delivered to each department in 2022 were obtained from Danish IPC retailers.

Results:

Of the 23 identified departments, 20 completed the survey. IPCs were available in all five Danish healthcare regions, but heterogeneity was observed in prevalence, reimbursement methods, procedural organization, and follow-up strategies. IPC use was more prevalent in respiratory medical departments and in the North and Central Regions. No standardized national reimbursement policy was identified.

Conclusion:

This survey reveals regional disparities in IPC use and reimbursement in Denmark within the same public healthcare system. The lack of national guidelines and centralized funding mechanisms may contribute to these variations. The introduction of dedicated pleural clinics and standardized reimbursement policies could help ensure equitable and guideline-based MPE management across regions.

2026-12-01·Clinical Proteomics

Proteomics analysis of aqueous and vitreous humor in uveitis: a systematic literature review

Review

作者: Vorum, Henrik ; Cehofski, Lasse Jørgensen ; Reeg, Susanne ; Subhi, Yousif ; Klefter, Oliver Niels ; Honoré, Bent

Abstract:

Purpose:

Uveitis is an inflammatory ocular disease with diverse etiologies and pathogeneses. It potentially leads to significant visual impairment and socioeconomic burden. Proteomic analysis can provide insights into protein-driven mechanisms that may improve diagnosis, monitor disease progression, and identify therapeutic targets. Here, we summarize the proteomic results from studies investigating the aqueous and vitreous humor in eyes with uveitis versus non-inflammatory controls.

Methods:

A comprehensive search of 15 databases was conducted on January 26, 2024. Studies were included if they performed proteomic analyses using mass spectrometry on aqueous or vitreous humor from uveitis patients. The selection, data extraction, and risk of bias assessment were performed independently by multiple reviewers, with a third reviewer consulted in case of disagreement. Six studies met the eligibility criteria, comprising 176 eyes of uveitis patients and 105 control eyes.

Results:

Two proteins, complement C1q subcomponent subunit B and C1q subcomponent subunit C, were consistently upregulated in five studies, underscoring the role of complement activation in uveitis pathogenesis. Three additional proteins − alpha-2-HS-glycoprotein, apolipoprotein A-I, and alpha-1-antichymotrypsin − were upregulated in four studies, highlighting the significance of inflammatory modulation. Ceruloplasmin, an acute-phase reactant, was upregulated in four studies. Gelsolin kininogen-1, and alpha-1-antitrypsin were upregulated in three studies, indicating a pro-inflammatory shift towards increased vascular permeability and recruitment of inflammatory cells.

Conclusion:

The identified proteome changes highlight central biological processes in uveitis, notably complement activation, acute-phase response, pro-inflammatory shift, and increased vascular permeability. The identified proteins can potentially support future diagnostic and therapeutic advances in uveitis.

项与 Odense University Hospital 相关的新闻（医药）

2025-10-31

·drugs

Mechanisms of Retinal Impairment ID'd in Idiopathic Intracranial HTN

THURSDAY, Oct. 30, 2025 -- Two mechanisms of structural and functional retinal impairment based on papilledema severity have been identified among patients with idiopathic intracranial hypertension (IIH), according to a study published online Oct. 29 in Neurology . Laleh D. Molander, M.D., from Odense University Hospital in Denmark, and colleagues conducted a prospective cohort study at two tertiary headache centers from January 2018 to September 2022, including 154 adult patients with IIH to map patterns of structural and functional retinal damage according to papilledema severity. The researchers identified two mechanisms of structural and functional retinal damage according to papilledema severity. The first was impairment of the retinal nerve fiber layer, with increasing papilledema severity paralleled by increasing atrophy of the retinal nerve fiber layer and the ganglion cell layer, yielding peripheral scotomata, which did not affect visual acuity. The second mechanism was macular impairment, with persisting reduction of visual acuity resulting from grade 4 papilledema combined with macular edema, macular exudate, or disorganization of the inner retinal layer. A score was proposed to predict visual outcome using modified desirability of outcome ranking. There was a correlation for the score with papilledema severity and disorganization of the inner retinal layer, but no correlation with lumbar puncture opening pressure, neurofilament light chain, or magnetic resonance imaging characteristics associated with IIH. "This score needs to be validated by external groups before it can be considered ready for use, but we identified the severity of papilledema and the disorganization of the inner layer of the retina as major predictors for who will have persistent vision problems," coauthor Dagmar Beier, M.D., from the University of Southern Denmark, said in a statement. Several authors disclosed ties to the pharmaceutical industry. Abstract/Full Text (subscription or payment may be required)

临床结果

2025-04-25

·PRNewswire

Odense University Hospital selects RayStation

STOCKHOLM, April 25, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that Odense University Hospital (OUH), which is part of the South Denmark Region, has placed an order for RayStation®*. The radiotherapy center at OUH is known for being at the forefront of automated solutions to provide high-quality care in an efficient way, including the ability to automatically generate treatment plans. With the introduction of RayStation, the clinic is now taking the next step by further developing automation to cover all aspects of the treatment planning process-from initial planning to finalized treatment plans. RayStation was chosen after an extensive evaluation of the market, where the decisive factor was to find a system that would enable OUH to continue developing new automated methods. RaySearch has had a strong focus on automation for a long time. RayStation offers several approaches for automated planning, both using machine learning techniques but also more conventional automated planning algorithms. In the upcoming version of RayStation, a new algorithm for automated optimization, which is still under development and led by Memorial Sloan Kettering Cancer Center in the US, will be included. The objective of the implementation project at Odense's radiotherapy center is to analyze the advantages of different auto-planning approaches and to clinically apply the approach that is best suited for each tumor site. Henrik Robenhagen Jensen, Chief Physicist, Odense University Hospital: "Odense University Hospital has long been dedicated to enhancing the quality of treatment planning, with a strong research focus on improving outcomes for cancer patients through state-of-the-art radiotherapy technologies. We are excited to begin our collaboration with RaySearch, which we see as a significant step forward. This partnership holds great promise for advancing automated treatment planning, with a clear emphasis on quality, efficiency, and the optimal use of clinical resources." Johan Löf, founder and CEO, RaySearch: "We have long been committed to increasing the degree of automation in RayStation. We are therefore particularly pleased that Odense University Hospital has chosen RayStation primarily based on this functionality. I am convinced that we will meet the center's requirements for automation and look forward to their feedback and a fruitful cooperation." The order value is DKK 10.5 million (approximately SEK 15.4 million), excluding service contract, of which the majority will be recognized as revenue in the first quarter of 2025. * Subject to regulatory clearance in some markets. For more information, please contact: Johan Löf, founder and CEO, RaySearch Laboratories AB (publ) Telephone: +46 (0) 8 510 530 00 [email protected]  Learn more about us on: LinkedIn YouTube This information was brought to you by Cision The following files are available for download: SOURCE RaySearch Laboratories WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-01-14

·drugs

Semaglutide Doubles Risk for Nonarteritic Anterior Ischemic Optic Neuropathy

TUESDAY, Jan. 14, 2025 -- Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes , according to a study published online Dec. 18 in the International Journal of Retina and Vitreous . Jakob Grauslund, D.M.Sci., Ph.D., M.D., from Odense University Hospital in Denmark, and colleagues prospectively evaluated the use of semaglutide and risk for NAION in people with type 2 diabetes. The analysis included 424,152 individuals (2018 to 2024) exposed (106,454 individuals) or not exposed (317,698 individuals) to once-weekly semaglutide. The researchers found that semaglutide exposure was significantly associated with a higher incidence rate (0.228 versus 0.093 per 1,000 person-years) and independently predicted a higher risk for upcoming NAION (hazard ratio, 2.19), even when accounting for multiple other factors. Of the 67 persons exposed to semaglutide who developed NAION, there was a median time from first prescription to event of 22.2 months (interquartile range, 10.2 to 37.8 months). "During five years of observation of all persons with type 2 diabetes in Denmark, use of once-weekly semaglutide independently more than doubled the risk of NAION," the authors write. "Given the irreversible nature of NAION, it is important to acknowledge this risk, and upcoming studies should aim to identify high-risk subgroups." Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果

100 项与 Odense University Hospital 相关的药物交易

登录后查看更多信息

100 项与 Odense University Hospital 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2026年03月20日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Faecal microbiota transplantation(Odense University Hospital)	克罗恩病更多	临床2期
AZD-1305 ( L-type calcium channel x Nav1.5 x hERG )	心房颤动更多	临床2期
[58mCo]Co-DOTA-hEGF	胶质母细胞瘤更多	临床前
135La-DOTA-hEGF	胶质母细胞瘤更多	临床前
Adipose-Derived Regenerative Cells(Odense University Hospital)	下肢溃疡更多	无进展